Patents Assigned to Incyte Corporation
  • Patent number: 12030885
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: July 9, 2024
    Assignee: Incyte Corporation
    Inventors: Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue, Artem Shvartsbart, David M. Burns, Daniel Levy
  • Patent number: 12030883
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: September 20, 2022
    Date of Patent: July 9, 2024
    Assignee: Incyte Corporation
    Inventors: Peter Carlsen, Ken Mukai, Haolin Yin, Xiaozhao Wang, Wenqing Yao, Wenyu Zhu
  • Patent number: 12030889
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: July 9, 2024
    Assignee: Incyte Corporation
    Inventors: Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
  • Patent number: 12030884
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: September 30, 2022
    Date of Patent: July 9, 2024
    Assignee: Incyte Corporation
    Inventors: Wenyu Zhu, Xiaozhao Wang, Wenqing Yao
  • Patent number: 12030882
    Abstract: The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: June 2, 2022
    Date of Patent: July 9, 2024
    Assignee: Incyte Corporation
    Inventors: Shili Chen, Zhongjiang Jia, Pingli Liu, Lei Qiao, Yongzhong Wu, Jiacheng Zhou, Qun Li
  • Publication number: 20240218070
    Abstract: The present disclosure relates to polypeptides, FAP binding domains comprising such polypeptides, and binding domains comprising such FAP binding domains. The present disclosure further relates to the use of such binding domains or binding moieties in the treatment of cancer. This disclosure further relates to a bispecific binding moiety comprising a FAP binding domain and a TGF-?RII binding domain. This disclosure further relates to a pharmaceutical composition comprising an effective amount of said bispecific binding moiety, and to methods for treating a disease in a subject, comprising administering a therapeutically effective amount of said bispecific binding moiety.
    Type: Application
    Filed: December 19, 2023
    Publication date: July 4, 2024
    Applicants: MERUS N.V., INCYTE CORPORATION
    Inventors: Cecilia Anna Wilhelmina GEUIJEN, Rinse KLOOSTER, Amaya GARCIA DE VINUESA ANTUNANO, Patrick MAYES, Horatio G. NASTRI, Stephen RUDNICK, Bindu VARGHESE, Moses DONKOR
  • Patent number: 12024522
    Abstract: The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3K?), as well as a salt form and intermediates related thereto.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: July 2, 2024
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Lei Qiao, Lingkai Weng, Chongsheng Eric Shi, David Meloni, Qiyan Lin, Michael Xia, Vaqar Sharief, William Frietze, Zhongjiang Jia, Yongchun Pan, Pingli Liu, Tai-Yuen Yue, Jiacheng Zhou, Jianji Wang
  • Patent number: 12024517
    Abstract: The present invention relates to salt forms of the Fibroblast Growth Factor Receptors (FGFR) inhibitor 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3?,2?:5,6]pyrido[4,3-d]pyrimidin-2-one, including methods of preparation thereof, where the compound is useful in the treatment of FGFR mediated diseases such as cancer.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: July 2, 2024
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, Jiacheng Zhou, Qun Li
  • Patent number: 12018089
    Abstract: Anti-CD73 antibodies are disclosed. Also disclosed are related nucleic acids, vectors, cells, and pharmaceutical compositions. Methods of treating cancer with the anti-CD73 antibodies are also disclosed.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: June 25, 2024
    Assignee: Incyte Corporation
    Inventors: Horacio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane
  • Patent number: 12012409
    Abstract: The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: June 18, 2024
    Assignee: Incyte Corporation
    Inventors: Jeremy Roach, Artem Shvartsbart, Michael Witten, Wenqing Yao
  • Patent number: 12005067
    Abstract: The present disclosure relates to topical treatment of skin diseases, such as psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization, using (a) a JAK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) vitamin D3, a vitamin D3 analog, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: June 11, 2024
    Assignee: Incyte Corporation
    Inventors: Paul Smith, Zheng Zhang, Melissa Parker, James Fidge
  • Patent number: 12006320
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: June 11, 2024
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Yanran Ai, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao, Artem Shvartsbart
  • Patent number: 11999740
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: June 4, 2024
    Assignee: Incyte Corporation
    Inventors: Xiaozhao Wang, Peter Niels Carlsen, Pei Gan, Gia Hoang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Wenyu Zhu
  • Patent number: 11999751
    Abstract: This application relates to derivatives of Formula I: and pharmaceutically acceptable salts thereof, which are inhibitors of PI3K, and compositions and methods of treatment related thereto.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: June 4, 2024
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Andrew P. Combs
  • Patent number: 11999752
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: June 4, 2024
    Assignee: Incyte Corporation
    Inventors: Peter Carlsen, Xiaozhao Wang, Alexander Sokolsky, Pei Gan, Rocco Policarpo, Wenqing Yao
  • Patent number: 11992490
    Abstract: The present application provides methods of treating a disease selected from cutaneous lupus erythematosus (CLE) and Lichen planus (LP) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a JAK1 selective inhibitor, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: May 28, 2024
    Assignee: Incyte Corporation
    Inventors: Paul Smith, Jörg Wenzel
  • Patent number: 11993654
    Abstract: The present disclosure relates to novel PD-1 binding domains that have a higher binding affinity for human PD-1 than a reference PD-1 binding domain. The PD-1 binding domains of the present disclosure further provide a comparable, or equal or higher, potency in blocking ligand binding to human PD-1 than a reference PD-1 antibody. The present disclosure further relates to binding moieties comprising such PD-1 binding domains. Also provided is a method for treating a disease, in particular a disease associated with a suppressed immune system, such as cancer, with a PD-1 binding domain or binding moiety of the present disclosure. The present disclosure further relates to nucleic acids encoding the heavy chain variable region of the PD-1 binding domains, and a vector and cell comprising such nucleic acid.
    Type: Grant
    Filed: March 31, 2022
    Date of Patent: May 28, 2024
    Assignees: MERUS N.V., INCYTE CORPORATION
    Inventors: Simon Edward Plyte, Patrick Mayes, Horacio G. Nastri, Shaun M. Stewart, Rebecca A. Buonpane
  • Patent number: 11981671
    Abstract: The present application provides bicyclic amines of Formula (I): or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: June 21, 2022
    Date of Patent: May 14, 2024
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, Jingwei Li, Ding-Quan Qian, Liangxing Wu
  • Patent number: 11976073
    Abstract: The present application provides bicyclic amines of Formula (I): and their pharmaceutically acceptable salts thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: May 7, 2024
    Assignee: Incyte Corporation
    Inventors: Joshua Hummel, David M. Burns, Ding-Quan Qian, Xiaozhao Wang
  • Patent number: 11957661
    Abstract: This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.
    Type: Grant
    Filed: December 8, 2021
    Date of Patent: April 16, 2024
    Assignee: Incyte Corporation
    Inventors: Paul Smith, Kurt Andrew Brown, Michael D. Howell, Fiona Kuo, James Lee, Leandro Luiz Dos Santos, Beth Rumberger